Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Radiotherapy in BCG-unresponsive NMIBC (PREVERT)
NCT03950362Phase 2Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of avelumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Institut Paoli-Calmettes. Status: unknown.
02
Drugs
avelumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03950362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950362.